Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986278 in Pulmonary Fibrosis
2019-003992-21Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) comparing BMS-986278 with Placebo (2 arms). Primary endpoint: Rate of change in ppFVC from baseline to Week 26 in IPF participants. Started May 2020; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2019-003992-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003992-21.